title: Anaphylactic reaction after initial exposure of Basiliximab: case reports.
abstract: Basiliximab is potent, relatively safe immunosuppressive induction agent used in transplantation. Prophylactic use at the time of transplantation has been advocated to improve allograft outcomes. We report two cases of kidney transplant recipients with anaphylactic reactions after initial exposure to Basiliximab.
authors: Department of Urology, St Marianna University School of Medicine, Kanagawa, Japan. sr20det@marianna-u.ac.jp
authors: H
authors: H
authors: Sasaki
authors: T
authors: T
authors: Chikaraishi
authors: S
authors: S
authors: Furuhata
authors: H
authors: H
authors: Tsutsumi
authors: S
authors: S
authors: Miyano
authors: T
authors: T
authors: Nakano
authors: Y
authors: Y
authors: Sato
authors: K
authors: K
authors: Kimura
authors: T
authors: T
authors: Takahashi
mesh_terms: D000293:Adolescent; D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000077552:Basiliximab; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011993:Recombinant Fusion Proteins / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab